BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17694300)

  • 1. Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.
    Panhard X; Legrand M; Taburet AM; Diquet B; Goujard C; Mentré F;
    Eur J Clin Pharmacol; 2007 Nov; 63(11):1019-29. PubMed ID: 17694300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
    Brendel K; Legrand M; Taburet AM; Baron G; Goujard C; Mentré F;
    Fundam Clin Pharmacol; 2005 Jun; 19(3):373-83. PubMed ID: 15910662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
    Panhard X; Goujard C; Legrand M; Taburet AM; Diquet B; Mentré F;
    Br J Clin Pharmacol; 2005 Oct; 60(4):390-403. PubMed ID: 16187971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
    Winston A; McAllister J; Amin J; Cooper DA; Carr A
    HIV Med; 2005 May; 6(3):191-7. PubMed ID: 15876286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
    Duval X; Peytavin G; Albert I; Bénoliel S; Ecobichon JL; Brun-Vézinet F; Mentré F; Leport C; Vildé JL
    HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
    Hosseinipour MC; Corbett AH; Kanyama C; Mshali I; Phakati S; Rezk NL; van der Horst C; Kashuba AD
    AIDS; 2007 Jan; 21(1):59-64. PubMed ID: 17148968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team.
    Aweeka FT; Kang M; Yu JY; Lizak P; Alston B; Chung RT;
    HIV Med; 2007 Jul; 8(5):288-94. PubMed ID: 17561874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products.
    Marier JF; Dimarco M; Guilbaud R; Dodard C; Morelli G; Tippabhotla SK; Singla AK; Thudi NR; Monif T
    J Clin Pharmacol; 2007 Nov; 47(11):1381-9. PubMed ID: 17962426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials.
    Rojas C; Coplan PM; Rhodes T; Robertson MN; DiNubile MJ; Guess HA
    Pharmacoepidemiol Drug Saf; 2003; 12(5):361-9. PubMed ID: 12899109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis.
    Jullien V; Raïs A; Urien S; Dimet J; Delaugerre C; Bouillon-Pichault M; Rey E; Pons G; Blanche S; Tréluyer JM
    Br J Clin Pharmacol; 2007 Jul; 64(1):105-9. PubMed ID: 17324223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients.
    Zhou XJ; Havlir DV; Richman DD; Acosta EP; Hirsch M; Collier AC; Tebas P; Sommadossi JP;
    AIDS; 2000 Dec; 14(18):2869-76. PubMed ID: 11153668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of antiretroviral drugs.
    Hoetelmans RM
    Antivir Ther; 1999; 4 Suppl 3():29-41. PubMed ID: 16021869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular studies of the nucleoside reverse transcriptase inhibitor active metabolites: a review.
    Rodriguez Orengo JF; Santana J; Febo I; Diaz C; Rodriguez JL; Garcia R; Font E; Rosario O
    P R Health Sci J; 2000 Mar; 19(1):19-27. PubMed ID: 10761201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
    Fletcher CV; Yogev R; Nachman SA; Wiznia A; Pelton S; McIntosh K; Stanley K
    Pharmacotherapy; 2004 Apr; 24(4):453-9. PubMed ID: 15098798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
    Currier J; Lazzarin A; Sloan L; Clumeck N; Slims J; McCarty D; Steel H; Kleim JP; Bonny T; Millard J;
    Antivir Ther; 2008; 13(2):297-306. PubMed ID: 18505181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.
    Solas C; Gagnieu MC; Ravaux I; Drogoul MP; Lafeuillade A; Mokhtari S; Lacarelle B; Simon N
    Ther Drug Monit; 2008 Dec; 30(6):670-3. PubMed ID: 18806695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
    Fabbiani M; Di Giambenedetto S; Bracciale L; Bacarelli A; Ragazzoni E; Cauda R; Navarra P; De Luca A
    J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir.
    Bourry O; Brochard P; Souquiere S; Makuwa M; Calvo J; Dereudre-Bosquet N; Martinon F; Benech H; Kazanji M; Le Grand R
    AIDS; 2009 Feb; 23(4):447-54. PubMed ID: 19240457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
    Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
    Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.
    Bryson YJ; Mirochnick M; Stek A; Mofenson LM; Connor J; Capparelli E; Watts DH; Huang S; Hughes MD; Kaiser K; Purdue L; Asfaw Y; Keller M; Smith E;
    HIV Clin Trials; 2008; 9(2):115-25. PubMed ID: 18474496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.